AARD Investors Have Opportunity to Lead Aardvark Therapeutics, Inc. Securities Fraud Lawsuit

Rosen Law Firm said it is reminding potential lead plaintiffs about an October 13, 2026 deadline in an alleged securities fraud lawsuit involving Aardvark Therapeutics, Inc. The firm specifically noted investors who purchased (i) common stock that was pursuant to and/or traceable to the registration statement and prospectus tied to Aardvark’s February 13, 2025 initial public offering, and/or (ii) securities between February 13, 2025 and May 14, 2026, inclusive. The company is listed on NASDAQ under ticker AARD.